Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy

Gynecologic Oncology

Volumn 108, Issue 1, 2008, Pages 126-129

  Hirakawa, Makoto ^a   Nagai, Yutaka ^a   Inamine, Morihiko ^a   Kamiyama, Kazuya ^a   Ogawa, Kazuhiko ^a   Toita, Takafumi ^a   Murayama, Sadayuki ^a   Aoki, Yoichi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Concurrent chemoradiotherapy; Distant recurrence; Serum squamous cell carcinoma antigen; Squamous cell carcinoma of the cervix

Indexed keywords

CISPLATIN; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DATA ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FISHER EXACT TEST; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TIME SERIES ANALYSIS; TUMOR VOLUME; UNIVARIATE ANALYSIS; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SERPINS; UTERINE CERVICAL NEOPLASMS;

EID: 37349005471     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.08.091     Document Type: Article

References (19)

1. US Dept. of Health and Human Service. NCI Clinical Announcement (February 1999), Public Health Service, National Institutions of Health, Bethesda, MD
2. Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
3. Peters III W.A., Liu P.Y., Barrett II R.J., Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 (2000) 1606-1613
4. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
5. Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler W.C., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
6. Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs III C.L., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161
7. Fields A.L., Anderson P.S., Goldberg G.L., Wadler S., Beitler J., Sood B., et al. Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 61 (1996) 416-422
8. Kato H., and Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40 (1977) 1621-1628
9. Neunteufel W., Tatra G., and Bieglmayer C. Serum squamous cell carcinoma antigen levels in women with neoplasms of the lower genital tract and in healthy controls. Arch Gynecol Obstet 246 (1989) 243-250
10. Brioschi P.A., Bischof P., Delafosse C., and Krauer F. Squamous-cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma. Int J Cancer 47 (1991) 376-379
11. Senekjian E.K., Young J.M., Weiser P.A., Spencer C.E., Magic S.E., and Herbst AL. An evaluation of squamous cell cancer. Am J Obstet Gynecol 157 (1987) 433-439
12. Scambia G., Panici P.B., Baiocchi G., Amoroso M., Foti E., Greggi S., et al. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol 164 (1991) 631-636
13. Ngan H.Y., Wong L.C., Chan S.Y., and Ma H.K. Use of serum squamous cell carcinoma antigen assays in chemotherapy treatment response in carcinoma of the cervix. Gynecol Oncol 35 (1989) 259-262
14. Ngan H.Y., Chan S.Y., Wong L.C., Choy D.T., and Ma H.K. Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol 37 (1990) 260-263
15. Meier W., Eiermann W., Stieber P., Schneider A., Fateh-Moghadam A., and Hepp H. Experiences with SCC antigen, a new tumor marker for cervical cancer. Eur J Clin Oncol 25 (1989) 1555-1559
16. Ohno T., Nakayama Y., Nakamoto S., Kato S., Imai R., Nonaka T., et al. Management of serum squamous cell carcinoma antigen levels as a predictor of Radiation response in patients with carcinoma of the uterine cervix. Cancer 97 (2003) 3114-3120
17. Hong J.H., Tsai C.S., Lai C.H., Chang T.C., Wang C.C., Chou H.H., et al. Risk stratification of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone. Int J Radiat Oncol Biol Phys 63 (2005) 492-499
18. Kim Y.B., Cho J.H., Keum K.C., Lee C.G., Seong J., Suh C.O., et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. Gynecol Oncol 104 (2007) 58-63
19. Tinker A.V., Bhagat K., Swenerton K.D., and Hoskins P.J. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol 98 (2005) 54-58